Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 27.2
(0.0%)
SEK 27.2
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 278.74 Million SEK | 10.24% |
| 2022 | 252.86 Million SEK | 6.61% |
| 2021 | 237.17 Million SEK | 19.75% |
| 2020 | 198.06 Million SEK | -6.7% |
| 2019 | 212.27 Million SEK | 39.16% |
| 2018 | 152.54 Million SEK | 3.15% |
| 2017 | 147.88 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 290.69 Million SEK | 4.29% |
| 2024 Q3 | 857.2 Million SEK | 181.71% |
| 2024 Q2 | 304.29 Million SEK | 4.68% |
| 2023 Q3 | 272.76 Million SEK | 3.96% |
| 2023 Q4 | 278.74 Million SEK | 2.19% |
| 2023 Q1 | 269.68 Million SEK | 6.65% |
| 2023 Q2 | 262.36 Million SEK | -2.72% |
| 2023 FY | 278.74 Million SEK | 10.24% |
| 2022 Q3 | 257.59 Million SEK | 0.13% |
| 2022 Q2 | 257.25 Million SEK | 0.55% |
| 2022 Q1 | 255.85 Million SEK | 7.87% |
| 2022 FY | 252.86 Million SEK | 6.61% |
| 2022 Q4 | 252.86 Million SEK | -1.84% |
| 2021 Q1 | 212.87 Million SEK | 7.48% |
| 2021 FY | 237.17 Million SEK | 19.75% |
| 2021 Q4 | 237.17 Million SEK | 0.21% |
| 2021 Q3 | 236.68 Million SEK | 12.59% |
| 2021 Q2 | 210.21 Million SEK | -1.25% |
| 2020 FY | 198.06 Million SEK | -6.7% |
| 2020 Q3 | 188.79 Million SEK | -3.65% |
| 2020 Q2 | 195.94 Million SEK | -0.56% |
| 2020 Q1 | 197.05 Million SEK | -7.17% |
| 2020 Q4 | 198.06 Million SEK | 4.91% |
| 2019 Q4 | 212.27 Million SEK | 0.0% |
| 2019 FY | 212.27 Million SEK | 39.16% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 FY | 152.54 Million SEK | 3.15% |
| 2017 FY | 147.88 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -126.274% |
| Amniotics AB (publ) | 26.08 Million SEK | -968.562% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -4486.885% |
| BioArctic AB (publ) | 1.18 Billion SEK | 76.499% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 85.333% |
| Genovis AB (publ.) | 288.85 Million SEK | 3.501% |
| LIDDS AB (publ) | 17.65 Million SEK | -1478.845% |
| OncoZenge AB (publ) | 20.34 Million SEK | -1270.428% |
| Saniona AB (publ) | 64.14 Million SEK | -334.568% |
| Simris Alg AB (publ) | 174.55 Million SEK | -59.692% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 43.829% |
| AcouSort AB (publ) | 34.51 Million SEK | -707.652% |
| Active Biotech AB (publ) | 44 Million SEK | -533.511% |
| Camurus AB (publ) | 1.9 Billion SEK | 85.389% |
| Cantargia AB (publ) | 223.71 Million SEK | -24.6% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1774.672% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -227.062% |
| Mendus AB (publ) | 755.95 Million SEK | 63.127% |
| Kancera AB (publ) | 65.64 Million SEK | -324.638% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 77.849% |
| Lipum AB (publ) | 12.11 Million SEK | -2201.775% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -729.549% |
| NextCell Pharma AB | 81.28 Million SEK | -242.91% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 57.346% |
| Xintela AB (publ) | 18.39 Million SEK | -1415.33% |
| Ziccum AB (publ) | 14.97 Million SEK | -1761.775% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -823.822% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1290.874% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -98.258% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 63.575% |
| CombiGene AB (publ) | 120.61 Million SEK | -131.109% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -28.431% |
| Intervacc AB (publ) | 259.61 Million SEK | -7.37% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -135.327% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -346.871% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -564.327% |
| Corline Biomedical AB | 100.1 Million SEK | -178.453% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -57.375% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -348.489% |
| Aptahem AB (publ) | 63.02 Million SEK | -342.277% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 20.661% |
| Fluicell AB (publ) | 9.34 Million SEK | -2884.422% |
| Biovica International AB (publ) | 131.4 Million SEK | -112.122% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -426.083% |
| Abliva AB (publ) | 87.49 Million SEK | -218.569% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 63.333% |
| 2cureX AB (publ) | 16.62 Million SEK | -1576.662% |
| I-Tech AB | 152.44 Million SEK | -82.852% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 72.619% |
| Cyxone AB (publ) | 43.65 Million SEK | -538.518% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -254.223% |
| Biosergen AB | 7.2 Million SEK | -3770.921% |
| Nanologica AB (publ) | 77.42 Million SEK | -260.001% |
| SynAct Pharma AB | 228.01 Million SEK | -22.246% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -941.531% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 80.092% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -1184.369% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -16.934% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -3196.807% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -220.132% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -877.778% |